Truist Securities Downgrades Alnylam Pharmaceuticals to Hold, Lowers Price Target to $225

Benzinga · 11/02 15:38
Truist Securities analyst Danielle Brill downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Hold and lowers the price target from $315 to $225.